Xcout IntelSign inSubscribe

Inotiv competitors & alternatives

NOTVQMedical - Diagnostics & ResearchWest Lafayette, United States

The 12 closest competitors and alternatives to Inotiv among medical - diagnostics & research companies — ranked by similarity to what Inotiv actually does, not by market-cap band.

$390,419Market cap
1,945Employees
12Competitors listed

Subscribe to see Inotiv’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Inotiv

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. On June 3, 2026, Inotiv, Inc. along with its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Inotiv at a glance

Inotiv is a medical - diagnostics & research company headquartered in West Lafayette, United States. It is publicly listed (NOTVQ) with a market capitalisation of $390,419. Xcout tracks 24 named people at Inotiv, including Robert W. Leasure Jr. (President, Chief Executive Officer & Director).

Inotiv leadership

  • Robert W. Leasure Jr.President, Chief Executive Officer & Director
  • Robert Jr. LeasureChief Executive Officer, President, and Director
  • Lizanne MullerGroup President of RMS
  • John Gregory BeattieChief Operating Officer of DSA
  • Beth A. TaylorEVP & CFO
  • John E. Sagartz DiplomateACVPChief Strategy Officer & Director

18 more named people on record for Inotiv, with roles, board committees and tenure — see the full roster →

Recent Inotiv news

5 corporate events on record, with sources — see the full timeline →

Top 12 Inotiv competitors

Ranked by semantic similarity — how close each company is to Inotiv by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Charles River Laboratories International, Inc.CRL · BiotechWilmington, United States
67% matchPublic

Biotech

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Market cap$13.8B
Employees18,700
Charles River Laboratories International, Inc. competitors & alternatives →
トランスジェニックグループ2342 · BiotechFukuoka City, Japan
60% matchPublic

Biotech

Trans Genic Inc., a Japanese enterprise, specializes in the development, distribution, and licensing of genetically engineered animals and antibodies. Its operations are structured into two primary divisions: Drug Discovery Support Business and Investment Business. Within its Drug Discovery Support segment, the company offers a comprehensive array of services. These include the synthesis and analytical assessment of glycans (or sugar chains), alongside extensive non-clinical investigations crucial for pharmaceuticals, food products, cosmetics, and various chemical compounds. The firm conducts diverse safety evaluations for both food and pharmaceutical agents, and provides vital support for bioequivalence studies, encompassing clinical trials, pharmacokinetic measurements, and the compilation of clinical trial reports. Hospital support services are also part of its offerings. Furthermore, Trans Genic performs drug efficacy and pharmacological testing, provides strategic advisory services covering mergers & acquisitions, business restructuring, and succession planning, and undertakes contract manufacturing of items such as genetically engineered mice, antibodies, protein hypers, and expression cells. It also markets mouse models, associated products, and research reagents. Established in 1998, the company was initially known as Kumamoto Immunochemical Laboratories Inc. before rebranding as Trans Genic Inc. in April 2000. Its corporate headquarters are located in Fukuoka City, Japan.

Market cap$26.8M
Employees227
トランスジェニックグループ competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Inotiv and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Inotivand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →